T1	Participants 609 657	24 initial patients, 17 heterozygous FH patients
T2	Participants 766 860	The patients received 20 mg/day atorvastatin and 3 g/day colestimide or 40 mg/day atorvastatin
T3	Participants 862 898	Fifteen patients completed the trial
T4	Participants 1172 1250	each therapy was predominantly more effective in some patients than in others.
